The content on this site is intended for healthcare professionals only
Dr Shirish Gadgeel speaks to ecancer regarding the two-year follow-up of adagrasib monotherapy in patients with advanced or metastatic KRASG12C-mutated non-small cell lung cancer. The results were presented at the World Conference on Lung Cancer 2023.
The study showed a median overall survival of 14.1 months at 26.9 months follow-up. The 1-year OS rate was 52.8%, and the 2-year OS rate was 31.3%.
He continues to discuss the median progression-free survival which as 6.9 months, while the 1-year PFS rate was 35.0% and the 2-year PFS rate was 13.9%. Additionally, the objective response rate was 43%, with the median duration of response being 12.4 months.
The findings of the study indicate that adagrasib offers durable clinical benefit with no new safety signals.
Dr Gadgeel concludes by highlighting that these results are promising given the limited treatment options currently available for patients with advanced or metastatic KRASG12C-mutated non-small cell lung cancer.
Prostate cancer
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
